Ciprofibrate and Liver Tumors in Mice
Author Information
Author(s): M.S. Rao, R.S. Dwivedi, V. Subbarao, J.K. Reddy
Primary Institution: Northwestern University Medical School
Hypothesis
Ciprofibrate induces peroxisome proliferation and liver tumors in C57BL/6N mice.
Conclusion
Ciprofibrate is shown to induce liver tumors in a mouse strain that typically has a low incidence of spontaneous liver tumors.
Supporting Evidence
- Ciprofibrate caused a 9-fold increase in peroxisome proliferation in the liver.
- 57% of mice developed hepatic adenomas and 21% developed hepatocellular carcinomas after treatment.
- Control mice did not develop any liver tumors.
Takeaway
Ciprofibrate, a drug that lowers fat in the blood, can cause liver tumors in mice that usually don't get them.
Methodology
Male C57BL/6N mice were fed ciprofibrate at different concentrations for varying durations, and liver tumors were assessed.
Limitations
The study was limited to a specific mouse strain and the duration of treatment may not reflect long-term effects.
Participant Demographics
Male C57BL/6N mice, 5 to 6 weeks old.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website